Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001373604-24-000114
Filing Date
2024-12-16
Accepted
2024-12-16 09:50:36
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 9831
2 bmlletter.htm EX-1 3628
  Complete submission text file 0001373604-24-000114.txt   15145
Mailing Address 156 S. FIRST STREET ZIONSVILLE IN 46077
Business Address 156 S. FIRST STREET ZIONSVILLE IN 46077 317-344-6689
BML Investment Partners, L.P. (Filed by) CIK: 0001373604 (see all company filings)

EIN.: 383708345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D

Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Subject) CIK: 0001593899 (see all company filings)

EIN.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-91836 | Film No.: 241550366
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)